GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocular Therapeutix Inc (FRA:0OT) » Definitions » Debt-to-Asset

Ocular Therapeutix (FRA:0OT) Debt-to-Asset : 0.14 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ocular Therapeutix Debt-to-Asset?

Ocular Therapeutix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €1.42 Mil. Ocular Therapeutix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €67.03 Mil. Ocular Therapeutix's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €495.83 Mil. Ocular Therapeutix's debt to asset for the quarter that ended in Mar. 2024 was 0.14.


Ocular Therapeutix Debt-to-Asset Historical Data

The historical data trend for Ocular Therapeutix's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocular Therapeutix Debt-to-Asset Chart

Ocular Therapeutix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 0.22 0.29 0.43 0.33

Ocular Therapeutix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.53 0.51 0.33 0.14

Competitive Comparison of Ocular Therapeutix's Debt-to-Asset

For the Biotechnology subindustry, Ocular Therapeutix's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocular Therapeutix's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Debt-to-Asset falls into.



Ocular Therapeutix Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Ocular Therapeutix's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.454 + 75.013) / 231.139
=0.33

Ocular Therapeutix's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.419 + 67.034) / 495.831
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocular Therapeutix  (FRA:0OT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Ocular Therapeutix Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Ocular Therapeutix's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocular Therapeutix (FRA:0OT) Business Description

Traded in Other Exchanges
Address
24 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Ocular Therapeutix (FRA:0OT) Headlines

No Headlines